A 64-Year-Old Woman with Multifocal Pelvic Recurrence of Endometrial Cancer

Opening her discussion on a patient case of recurrent endometrial cancer, Ritu Salani, MD, MBA, highlights the evolving role of molecular testing in this setting.

An expert gynecologic oncologist shares her perspective on treatment options available to patients in the first- and second-line settings of endometrial cancer.

A focused review of clinical trial data that inform the use of immune checkpoint inhibition in the setting of recurrent endometrial cancer.

Closing out her discussion on the management of recurrent endometrial cancer, Ritu Salani, MD, MBA, shares clinical pearls amidst the shifting treatment paradigm.

Expert perspectives on the RUBY and GY018 trials, which tested dostarlimab and pembrolizumab, respectively, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.

Focused discussion on single-agent immunotherapy in patients with advanced endometrial cancer following data from the PHAEDRA and DOMENICA clinical trials.

A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.

Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.

Closing out her discussion on novel therapeutics in endometrial cancer, Ritu Salani, MD, MBA, shares excitement for ongoing evolutions within the treatment landscape.